Stoke Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 26.35 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.70B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i...